. 2023 Jul 1;10(3):97–100. doi: 10.5152/eurjrheum.2023.22086
Content of this journal is licensed under a Table 2.
Glucocorticoid-Induced Osteoporosis
| Q1 (N = 72) | Q2 (N = 54) | Q3 (N = 49) | |
|---|---|---|---|
| Entry into cohort | |||
| Single dose ≥ 30 mg | 73.2% | 55.6% | 51.0% |
| Cumulative dose ≥ 5000 mg | 82.1% | 96.2% | 85.7% |
| Test results | |||
| Serum vitamin D (normal) | 41.3% (19/46) | 52.8% (19/36) | 51.6% (16/31) |
| Bone mineral density (requested) | 31.9% (23/72) | 36.5% (19/52) | 40.4% (19/47) |
| Bone mineral density (normal) | 43.5% (10/23) | 10.5% (2/19) | 21.1% (4/19) |
| GIO prevention measures | |||
| Vitamin D supplementation | 18.1% | 61.1% | 67.3% |
| Bisphosphonates | 9.7% | 35.2% | 34.7% |
| RANKL inhibitors | 4.2% | 11.1% | 14.3% |
GIO, Glucocorticoid-Induced Osteoporosis; Q1, Quarter 1; Q2, Quarter 2; Q3, Quarter 3; Q4, Quarter 4; RANKL, receptor activator of nuclear factor-κB ligand.